Bruno Vivaldi

Urólogo 🇨🇱 | #Endourology #RoboticSurgery #Urolothiasis #KidneyTransplantation | @clinicauandes @hosmilsantiago

[Bruno Vivaldi @bvivaldi]

Inscripciones abiertas IV Curso @filialendouro @Urolchi - Innovación y Tecnología en Endourología

🗓9 septiembre 2022📍Hotel Plaza El Bosque 🇨🇱

✈️ sorteo 2 becas VI Curso Internacional de Endourología y Litiasis @HAlemanBsAs

https://t.co/HHiqWyE69y

[Bruno Vivaldi @bvivaldi]

Perioperative Apalutamide in High-Risk Localized Prostate Cancer | New England Journal of Medicine https://t.co/Qho4TGc8VH

[Bruno Vivaldi @bvivaldi]

@NFL_DovKleiman Good to sing a good traumatologyst

[Axel S. Merseburger @amerseburger]

Three studies:

• PAnTHA
• KEYNOTE-B15
• LITESPARK-022

from #ASCOGU2026 #GU26 that could potentially influence clinical practice in uro-oncology.

#Medudy @DrChoueiri #Prostatecancer #Bladdercancer #renalcellcarcinoma #DigitalHealth @OncoAlert @APCCC_Lugano @tompowles1

[Bruno Vivaldi @bvivaldi]

@RiseUpReader Yes 👍🏼

[Bruno Vivaldi @bvivaldi]

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms | American Society of Clinical Oncology Educational Book https://t.co/IonDDpTUJe

[Bruno Vivaldi @bvivaldi]

@urobraulio @Skonrado Excelente Braulio

[Javier Puente @docjavip]

KEYNOTE-B15/EV-304 trial is practice-changing: periop EV+ pem:
🔥 47% reduction in risk of events (HR 0.53)
🔥 Significant OS benefit (HR 0.65)
🔥 pCR 55.8% vs 32.5%
A true paradigm shift for cisplatin-eligible MIBC.
Honored to be part of this milestone with our HCSC team #GU26

[Bruno Vivaldi @bvivaldi]

@gonzacabala Milla

[Bruno Vivaldi @bvivaldi]

@DRSALVADOSTONE @FelipePauchard Mucha suerte a ambos! Abrazo

[Bruno Vivaldi @bvivaldi]

@LoboVilIage Tucu Contreras esta fuera de físico. Le faltan unos 5 kilos menos

[Bruno Vivaldi @bvivaldi]

@paugalvezc @e_bullanguera Seguro llego?

[UroToday.com @urotoday]

🧬 Preventing #ProstateCancer Progression During Active Surveillance 🧬

This systematic review/meta-analysis highlights the potential of nonsurgical interventions for prostate cancer patients on Active Surveillance:

5-alpha-reductase inhibitors (5-ARIs) ↓ risk of progression by 41%, without increasing treatment-related adverse events (TRAEs).
Mixed results for other therapies:
Effective: chlormadinone, FT inhibitors, enzalutamide, but with high TRAE rates ⚠️.
Limited benefit from lifestyle/diet interventions.
🔎 Challenges: Variability in biopsy protocols and PSA monitoring may skew findings.

Takeaway: Personalized strategies are crucial to optimize AS outcomes while minimizing risks.
Read Now > https://t.co/qQRU0yamsL @DrShariat @dr_rajwa

[More Births @MoreBirths]

The fastest fertility collapse in the world
In 2024 Chile recorded a fertility rate of just 0.88 births per woman, a drop of 23% in a year and 51% since 2015. No country has seen fertility fall as fast.
A look at how social changes have overwhelmed 🇨🇱 and threaten its future.
🧵!

[Bruno Vivaldi @bvivaldi]

@JohnFricke Cost a season!

[Bruno Vivaldi @bvivaldi]

@ErrorGramatica Frut

[Bruno Vivaldi @bvivaldi]

@CalderonBassi Negativo estimado

[Bruno Vivaldi @bvivaldi]

@LoboVilIage Aguantemos un poco. No ha recibido muchas!

[Bruno Vivaldi @bvivaldi]

@gonzalofullu Comparto Gonzalo!

[VSports Team @VSportsTM]

Athletic Club homenajeó a Miguel Ocio, hincha del club que falleció luego de haberse descompensado en la cancha en la SF de la Copa del Rey. Su familia colocó un ramo de flores en su localidad. Hacía 42 años que era socio.

[NephroPOCUS @NephroP]

Hydronephrosis
#POCUS #FOAMed #Nephpearls